Patents by Inventor Christopher M. Chumsae

Christopher M. Chumsae has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN ANTIBODIES THAT BIND HUMAN TNF-ALPHA AND METHODS OF PREPARING THE SAME
    Publication number: 20190048069
    Abstract: Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MGO-modified antibodies in the production of Adalimumab TNF-alpha antibodies.
    Type: Application
    Filed: February 28, 2018
    Publication date: February 14, 2019
    Applicant: AbbVie Inc.
    Inventor: Christopher M. CHUMSAE
  • METHODS FOR MODULATING THE GLYCOSYLATION PROFILE OF RECOMBINANT PROTEINS USING SUGARS
    Publication number: 20170355760
    Abstract: The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of recombinant proteins expressed in host cells.
    Type: Application
    Filed: May 5, 2017
    Publication date: December 14, 2017
    Inventors: Patrick Hossler, Sean McDermott, Christopher Racicot, Joseph G. Matuck, Keith Cochran, Christopher M. Chumsae
  • METHODS TO MODULATE LYSINE VARIANT DISTRIBUTION
    Publication number: 20170349655
    Abstract: The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the distribution or amount of lysine variants expressed by host cells, as well as to compositions and processes for controlling the amount of lysine variants present in purified preparations.
    Type: Application
    Filed: June 19, 2017
    Publication date: December 7, 2017
    Applicant: AbbVie Inc.
    Inventors: Kartik Subramanian, Mayda Perez Thiele, Xiaobei Zeng, Chee Furng Wong, Christopher M. Chumsae
  • Methods to modulate lysine variant distribution
    Patent number: 9708400
    Abstract: The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the distribution or amount of lysine variants expressed by host cells, as well as to compositions and processes for controlling the amount of lysine variants present in purified preparations.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: July 18, 2017
    Assignee: ABBVIE, INC.
    Inventors: Kartik Subramanian, Mayda Perez Thiele, Xiaobei Zeng, Chee Furng Wong, Christopher M. Chumsae
  • MODULATED LYSINE VARIANT SPECIES COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME
    Publication number: 20170121403
    Abstract: The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Application
    Filed: November 16, 2016
    Publication date: May 4, 2017
    Applicant: AbbVie, Inc.
    Inventors: Kartik SUBRAMANIAN, Mayda Perez THIELE, Xiaobei ZENG, Chee Furng WONG, Zehra KAYMAKCALAN, Ying JING, Christopher M. CHUMSAE
  • Human Antibodies that Bind Human TNF-Alpha and Methods of Preparing the Same
    Publication number: 20170029495
    Abstract: Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MGO-modified antibodies in the production of Adalimumab TNF-alpha antibodies.
    Type: Application
    Filed: October 18, 2016
    Publication date: February 2, 2017
    Inventor: Christopher M. CHUMSAE
  • Human antibodies that bind human TNF-alpha and methods of preparing the same
    Patent number: 9505833
    Abstract: Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MOO-modified antibodies in the production of Adalimumab TNF-alpha antibodies.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: November 29, 2016
    Assignee: AbbVie Inc.
    Inventor: Christopher M. Chumsae
  • Modulated lysine variant species compositions and methods for producing and using the same
    Patent number: 9499616
    Abstract: The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: November 22, 2016
    Assignee: ABBVIE INC.
    Inventors: Kartik Subramanian, Mayda Perez Thiele, Xiaobei Zeng, Chee Furng Wong, Zehra Kaymakcalan, Ying Jing, Christopher M. Chumsae
  • MODULATED LYSINE VARIANT SPECIES COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME
    Publication number: 20160237150
    Abstract: The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Application
    Filed: October 27, 2015
    Publication date: August 18, 2016
    Inventors: Kartik Subramanian, Mayda Perez Thiele, Xiaobei Zeng, Chee Furng Wong, Zehra Kaymakcalan, Ying Jing, Christopher M. Chumsae
  • Methods of Reducing Methylglyoxal (MGO) Modification of Recombinant Proteins in Cell Culture
    Publication number: 20160115225
    Abstract: Methods are provided for controlling the levels of acidic species when a protein of interest is expressed by host cells. One particular example of an acidic species is methylglyoxal (MGO). Reduction of acidic species such as MGO may be achieved by regulating the glucose consumption of the cell culture or by modulating the cysteine/glutathione metabolic pathways.
    Type: Application
    Filed: October 23, 2015
    Publication date: April 28, 2016
    Inventors: Christopher M. Chumsae, Kartik Subramanian, Yun ("Frank") Zhang
  • METHODS TO MODULATE LYSINE VARIANT DISTRIBUTION
    Publication number: 20160046708
    Abstract: The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the distribution or amount of lysine variants expressed by host cells, as well as to compositions and processes for controlling the amount of lysine variants present in purified preparations.
    Type: Application
    Filed: October 27, 2015
    Publication date: February 18, 2016
    Inventors: Kartik Subramanian, Mayda Perez Thiele, Xiaobei Zeng, Chee Furng Wong, Christopher M. Chumsae
  • Human antibodies that bind human TNF-alpha and methods of preparing the same
    Patent number: 9193787
    Abstract: Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MGO-modified antibodies in the production of Adalimumab TNF-alpha antibodies.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: November 24, 2015
    Assignee: ABBVIE INC.
    Inventor: Christopher M. Chumsae